Streetbeat News

Corporate Responsibility

VRTX

CervoMed has appointed Dr. Joshua Boger, the founder and retired CEO and Board Chair of Vertex Pharmaceuticals, as its Board Chair. The company is progressing with its RewinD-LB Phase 2b clinical trial for neflamapimod in patients with dementia with Lewy bodies, expecting to complete enrollment in the first half of 2024 and to release topline data in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:35 pm

FWRD

Forward Air Corporation has announced significant leadership changes, appointing Michael Hance as the Interim CEO, Chris Ruble as President and COO, and George Mayes as the Independent Chairman. These appointments mark a pivotal moment for the company as it navigates through its current phase.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:30 pm

EQIX

Equinix, Inc. (NASDAQ:EQIX) has executed a new Power Purchase Agreement (PPA) in Australia with TagEnergy for 151 megawatts of renewable energy from the Golden Plains Wind Farm – East project, expected to be online by 2029. This marks Equinix's first long-term renewable energy agreement in the Asia-Pacific region, contributing to its goal of 100% renewable energy coverage across its operations globally. Equinix has executed 21 PPAs globally, resulting in 3,000,000 MWh of renewable energy, and aims to become climate neutral by 2030.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:27 pm

IFNNY

WKSP

Infineon Technologies AG (IFNNY) and Worksport Ltd. (WKSP) have announced a collaboration to enhance the efficiency and reduce the size and cost of Worksport's portable power stations using Infineon's GaN power semiconductors. This partnership aims to decrease the weight of Worksport's battery system by 33% and system costs by up to 25%, while also reducing CO2 emissions in the manufacturing process. Infineon's GaN technology is highlighted as a game-changer in various markets, including data centers, where it can significantly save energy and reduce carbon emissions.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:26 pm

OGEN

Oragenics, Inc. (OGEN) announced the expiration of its investment banking engagement agreement, choosing not to extend it due to market conditions. The company is developing ONP-002, a neurosteroid for treating mild Traumatic Brain Injury (mTBI), showing promising preclinical results. The global market for concussion treatment is expected to grow from $6.9 billion in 2020 to $8.9 billion by 2027.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:19 pm

TERN

Terns Pharmaceuticals has announced the appointment of Amy Burroughs as its new CEO. This strategic leadership change aims to steer the company towards new growth opportunities and enhance its position in the pharmaceutical industry.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:17 pm

XTKG

X3 Holdings Co., Ltd. (NASDAQ:XTKG) has expanded its bitcoin mining operations by deploying 2,000 machines in Central Asia, leveraging hydro-powered and renewable energy sources for sustainability. This move is expected to significantly increase the company's mining capabilities with a hash rate of 0.28EH/s and marks a strategic step towards using eco-friendly energy solutions in its operations.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:15 pm

DMRC

Digimarc Corporation (NASDAQ:DMRC) announced the release of its next-generation digital watermarks, offering enhanced security, adaptability, imperceptibility, performance, and control. These advancements are designed to efficiently address multiple use cases and represent a significant improvement in digital watermarking technology.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:13 pm

CDAY

Dayforce projects Q1 2024 revenue to be between $424M-$427M, slightly below the $427.81M estimate, and forecasts FY24 revenue of $1.72B-$1.73B, under the $1.74B estimate. The company anticipates a 14%-15% year-over-year revenue increase for Q1 and a 14% increase for FY24, with Dayforce recurring revenue expected to grow 20%-22% in Q1 and 20%-21% for the full year. Adjusted EBITDA is projected at $123M-$126M for Q1 and $480M-$495M for FY24, reflecting investments in global expansion and the Dayforce platform scaling.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:12 pm

PCRX

Pacira BioSciences, Inc. (NASDAQ:PCRX) has entered into a national group purchasing agreement with Premier, Inc. for its non-opioid pain management solution, EXPAREL. This agreement, effective January 1, 2024, allows Premier members to access special pricing and terms for EXPAREL, aiming to improve patient care and reduce healthcare costs. The collaboration aligns with both companies' goals of advancing innovation and patient safety while expanding Pacira's reach in the U.S. healthcare market.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:11 pm